MedPath

Clinical Evaluation of the CINtec® Cytology Dual Stain Kit as a Screening Test as well as a Reflex Test in the Triage of Women with a Pap Cytology Result of ASC-US or LSI

Conditions
cervical cancer, High-grade lesion of cervix uteri
N87.2
Severe cervical dysplasia, not elsewhere classified
Registration Number
DRKS00000408
Lead Sponsor
mtm laboratories AG
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
27349
Inclusion Criteria

Women undergoing a routine cervical cancer screening based on Pap cytology testing or women with a Pap cytology result of ASC-US or LSIL based on liquid-based cytology and evaluated according to the Bethesda classification system,

Signed, written informed consent.

Exclusion Criteria

Women who are pregnant,

Women with a history of hysterectomy (except a supracervical hysterectomy),

Women who are unwilling or unable to provide informed consent and/or to adhere to study requirements.

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Evaluation of the senitivity and specificity of CINtec cytology Dual Stain for identifying HGCIN (CIN2+/CIN3+) employing the quality-controlled histology diagnosis of cervical biopsies as gold standard.
Secondary Outcome Measures
NameTimeMethod
Comparison of the sensitivity and specificity of CINtec Cytology Dual Staining for identifying HGCIN with the sensitivity and specificity of the follwing tests: <br>- Pap cytology<br>- HR-HPV test<br>
© Copyright 2025. All Rights Reserved by MedPath